In The News Posted August 31, 2022 Share Posted August 31, 2022 - Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mainland China on May 13, 2022 - Adjusted loss reduced to RMB 126 million for the first six months of 2022 from RMB 210 million in the same period last year - Cash and bank balances of RMB...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now